On Wednesday, shares of Monte Rosa Therapeutics (GLUE.US) surged more than 42% in pre-market trading to $22.76. The catalyst for the move was positive interim data from the ongoing Phase 1 trial of MRT-8102, showing a reduction in C-reactive protein levels associated with cardiovascular and cardiometabolic diseases. In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102—an investigational NEK7-targeting molecular glue degrader for treating NLRP3/IL-1/IL-6-driven inflammatory diseases—demonstrated rapid and sustained systemic reduction of inflammation. After four weeks of treatment with MRT-8102, C-reactive protein (CRP) levels decreased by 85%, and 94% of study participants achieved a CRP value below 2 mg/L, a threshold linked to a lower risk of cardiovascular disease.